Entera Bio (ENTX): Net earnings per share growth forecast for next year
Entera Bio Ltd. is developing a system to convert injections into tablets, ensuring high patient loyalty in osteoporosis treatment. This chart of the company's expected EPS growth for the coming year reflects the market consensus, where the value 18.60 captures the metric level. A patent monopoly on protein delivery provides the firm with pricing power, while technology licensing generates a steady cash flow and high margins.
Financial and market metric breakdowns for Entera Bio (ENTX)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Entera Bio Ltd.|ENTX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Entera Bio Ltd|ENTX - Company Cumulative Debt|Debt to Book Capitalization Ratio Entera Bio|ENTX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Entera Bio|Quick Liquidity Indicator enterabio.com
- earnings and valuation multiples information:
ENTX - Final Profit|Projected Future Earnings Entera Bio Ltd.|ENTX - Price to Earnings Ratio|Forward P/E Multiple Entera Bio Ltd|ENTX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Entera Bio|ENTX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Entera Bio|ENTX - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months enterabio.com|ENTX - Earnings per share growth in current year|Expected earnings per share growth for next year Entera Bio Ltd.
Fundamental company analysis:ENTX, Entera Bio Ltd.
Entera Bio Ltd. is developing patent-protected oral peptide delivery technology, which creates high barriers to entry for competitors. This analyst valuation of net profit dynamics for n+1 measures the expected growth rate of profit for the coming period, reflecting the market consensus regarding the monetization of intellectual property. The stability of the line indicates a balance between capital-intensive FDA trials and growth potential, determining the business's investment attractiveness.
Competitor analysis for Entera Bio Ltd.
HLN (Haleon Group) - Earnings growth forecast for next year|Expected net earnings per share growth next year Kenvue Health KVUE|Net earnings per share growth forecast for next year Verona Pharma plc (VRNA)|MENS (jyongbio.com) - Expected earnings per share trend next year|Earnings growth forecast for next year LGND (Ligand)|Amneal Pharmaceuticals, Inc. (AMRX) - Expected net earnings per share growth next year|PRGO - Net earnings per share growth forecast for next year|ALVO (Alvotech Biopharmaceuticals) - Projected earnings per share growth rate for next year|LQDA (Liquidia Corporation) - Expected earnings per share growth for next year|GLPG: Projected earnings per share increase next year|ANIP (ANI Pharmaceuticals, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year MannKind Corp MNKD|Net earnings per share growth forecast for next year Amphastar (AMPH)|PCRX (Pacira Corp) - Expected earnings per share trend next year|Earnings growth forecast for next year SPRY (ARS Pharmaceuticals)|Earnings growth forecast for next year theravance.com TBPH|AQST: Expected earnings per share growth for next year|Expected earnings per share trend next year SCPH (scPharmaceuticals Inc.)|TECX: Earnings growth forecast for next year|TNXP (Tonix Pharmaceuticals Holding) - Net earnings per share growth forecast for next year|SXTC (SXT Pharmaceuticals) - Earnings growth forecast for next year|Eupraxia Pharma (EPRX) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year BioHarvest Sciences Inc. (BHST)|EXOZ - Expected net earnings per share growth next year|Oramed Pharmaceuticals Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year HYFT|ABVC - Net earnings per share growth forecast for next year|CPIX: Net earnings per share growth forecast for next year|QNTM (Quantum BioPharma) - Expected earnings per share growth for next year|FGEN: Projected earnings per share increase next year|TELO (Telomir Pharma) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year RANI (Rani Therapeutics Inc)|Expected earnings per share growth for next year SNYR (Synergy CHC Corp)|Consensus forecast of earnings per share growth for next year rallybio.com|Earnings growth forecast for next year LEXX (Lexaria Bioscience Corp.)|Pulmatrix Inc (PULM) - Expected net earnings per share growth next year|PTHL - Net earnings per share growth forecast for next year|APM (Aptorum Group Limited) - Projected earnings per share growth rate for next year|LYRA (Lyra Therapeutics, Inc.) - Expected earnings per share growth for next year|IBO: Projected earnings per share increase next year|Expected earnings per share growth for next year TNFA|Projected earnings per share growth rate for next year YCBD (cbdMD Corp)|Net earnings per share growth forecast for next year PainReform Limited (PRFX)|CYTO: Net earnings per share change forecast for next year|Earnings growth forecast for next year LIPO (Lipella Pharmaceuticals)|Expected earnings per share trend next year OPTN|Pieris Pharmaceuticals, Inc. - Earnings growth forecast for next year|PROC - Earnings growth forecast for next year|Petros (PTPI) - Net earnings per share growth forecast for next year|Qilian International Corp - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Acelyrin, Inc.|Expected earnings per share growth for next year tffpharma.com (TFFP)
